• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Avatrombopag Maleate
BioHub® Magnetic Separator
Avatrombopag
Ursodeoxycholic acid
Troxerutin
CytoLinX® BRTF Single-use Top-driven Bioreactor Bag

Philippines gets 1 million more Sinovac doses

firstwordpharmaJune 07, 2021

Tag: Sinovac , COVID-19 , Vaccine

The Philippines on Sunday received 1 million more doses of Sinovac's COVID-19 vaccine as part of its procurement of the vaccine, as reported The Philippine Star.

Philippines gets 1 million more Sinovac doses

The shipment brought the number of Sinovac doses in the country to 6.5 million, of which around 1 million were donated by Beijing.

Vaccine czar Carlito Galvez Jr. has said the country is expecting around 10 million doses to arrive this month.

Other vaccines in the country aside from Sinovac are: AstraZeneca and Pfizer from the COVAX Facility and Sputnik V from Russia.

Previous:Anvisa allows import of Covaxin, Sputnik V into Brazil, but conditions apply

Next:Understanding molecular actions may be key in treating severe COVID-19 cases: Study

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Philippines gets 1 million more Sinovac doses | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Hualan

Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Hualan
Group ACYW135 Meningococcal Polysaccharide Vaccine with lower adverse effect

Group ACYW135 Meningococcal Polysaccharide Vaccine with lower adverse effect
Hualan BIO Influenza Vaccine (Split virion)

Hualan BIO Influenza Vaccine (Split virion)
H7N9 Inactivated Influenza Vaccine-HUALAN BIO

H7N9 Inactivated Influenza Vaccine-HUALAN BIO
Hualan-Inactivated Influenza Vaccine(Split Virion) manufactured by Hualan Bio

Hualan-Inactivated Influenza Vaccine(Split Virion) manufactured by Hualan Bio
Influenza Vaccine 2022

Influenza Vaccine 2022
Group ACYW135 Meningococcal Polysaccharide Vaccine

Group ACYW135 Meningococcal Polysaccharide Vaccine

Quadrivalent Influenza Vaccine, Inactivated (HUALAN BIO)

Quadrivalent Influenza Vaccine, Inactivated (HUALAN BIO)
Hualan Biological inactivated flu vaccine

Hualan Biological inactivated flu vaccine
Influenza Vaccine（Split Virion）,Inactivated，Quadrivalent

Influenza Vaccine（Split Virion）,Inactivated，Quadrivalent

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service